CHMP grants positive opinion for Roche's Kadcyla, the first antibody-drug conjugate for advanced HER2-positive breast cancer

Roche today announced that the European Union’s (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Kadcyla (trastuzumab emtansine or T-DM1) as a single agent, for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news